Novel insights into the mechanism of action of intravesical immunomodulators

In Vivo

Volumn 19, Issue 3, 2005, Pages 611-622

  Mitropoulos, Dionisios N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bacillus Calmette Guerin; Bladder cancer; Interferon; Intravesical treatment; Review

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA2B INTERFERON; BCG VACCINE; CYCLOOXYGENASE 1; EPIRUBICIN; FAS LIGAND; FIBRONECTIN; IMMUNOMODULATING AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MITOMYCIN C; PERFORIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; ENZYME INHIBITION; HUMAN; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RECEPTOR DENSITY; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSITIONAL CELL CARCINOMA;

EID: 17644396990     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (179)

1. Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999.
2. Cutler SJ, Heney NM and Friedell GH: Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In: AUA Monographs, Vol 1: Bladder Cancer (Bonney WW and Prout GRJr, eds), Baltimore, Williams and Wilkins, pp. 35-46.
3. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD and Hawkins IR: Superficial bladder cancer: progression and recurrence. J Urol 130: 1083-1086, 1983.
4. Bubenik J, Kieler J, Tromholt V, Hermann G and Jandlova T: Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Immunol Lett 18: 115-118, 1988.
5. Richner J, Ambinder EP, Hoffman K, Feuer EJ and Bekesi G: Number of helper T cells and phytohemagglutinin stimulation correlate in cancer patients. Cancer Immunol Immunother 34: 138-142, 1991.
6. Kaver I, Pecht M, Trainin N, Greenstein A and Braf Z: T-lymphocyte subsets and function in the peripheral blood of patients with urological cancer. Oncology 49: 108-113, 1992.
7. Tsujihashi H, Uejima S, Akiyama T and Kurita T: Immunohistochemical detection of tissue-infiltrating lymphocytes in bladder tumors. Urol Int 44: 5-9, 1989.
8. Flamm J: Tumor-associated tissue inflammatory reaction and eosinophilia in primary superficial bladder cancer. Urology 40: 180-185, 1992.
9. Witjes JA, Mulders PF and Debruyne FM: Intravesical therapy in superficial bladder cancer. Urology 43(2suppl): 2-6, 1994.
10. Kilbridge KL and Kantoff P: Intravesical therapy for superficial bladder cancer: is it a wash? J Clin Oncol 12: 1-4, 1994.
11. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ and Hughes TK: The interferons. Mechanism of action and clinical applications. JAMA 266: 1375-1383, 1991.
12. Kostakopoulos A, Deliveliotis C, Mavromanolakis E, Aravantinos G and Dimopoulos MA: Interferon alpha-2b administration in the treatment of superficial bladder tumors. Eur Urol 18: 201-205, 1990.
13. Giannakopoulos S, Gekas A, Alivizatos G, Sofras F, Becopoulos T and Dimopoulos C: Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol 82: 829-834, 1998.
14. Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M and Hannigan J: Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group study. J Clin Oncol 6: 476-483, 1988.
15. Glashan R: A randomized controlled study of intravesical α2b interferon in carcinoma in situ of the bladder. J Urol 144: 658-661, 1990.
16. Boccardo F, Cannata D, Rubagotti A, Guarneri D, Decensi A, Canobbio L, Curotto A, Martorana G, Fegoraro C and Selvaggi P: Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: results of a multicentric Italian study. J Clin Oncol 12: 7-13, 1994.
17. Kurzrock R, Gutterman JU and Talpaz M: Interferons-α, β, γ: basic principles and preclinical studies. In: Biologic Therapy of Cancer (DeVita VT Jr, Hellman S and Rosenberg SA, eds). Philadelphia, JB Lippincott Co, pp. 247-274, 1991.
18. Borden E, Groveman D, Nasu T, Reznikoff C and Bryan GT: Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 132: 800-803, 1984.
19. Dianzani F: Biological basis for therapy and for side effects. In: Interferon: Principles and Medical Applications (Boron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK Jr, Klimpel GR, Niesel DW, Stanton GJ and Tyring SK, eds), Galveston: The University of Texas, pp. 409-416.
20. Fuchsberger N, Kubes M, Kontsek P, Borecky L, Hornak M, Godal A, Silvanova and Svec J: In vitro antiproliferative effect of interferon alpha in solid tumors: a potential predictive test. Neoplasma 40: 293-296, 1993.
21. Giannopoulos A, Constantinides C, Kortsaris A, Chrisofos M, Pavlaki C and Dimopoulos C: Determination of interfeon-alpha receptors in urothelial cancer and in normal urothelium. J Urol 157: 79-82, 1997.
22. Giannopoulos A, Adamakis I, Evangelou K, Giannopoulou M, Zacharatos P, Zsantoulis P, Perunovic B, Athanasiou A, Retalis G, Constantinides C and Gorgoulis VG: Interferon-α2b reduces neo-microvascular density adjacent to the tumor after transurethral resection of superficial bladder carcinoma. Onkologie 26: 147-152, 2003.
23. Bostrom PJ, Uotila P, Rajala P, Nurmi M, Huhtaniemi I and Laato M: Interferon-alpha inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. Urol Res 29: 20-24, 2001.
24. Stravoravdi P, Belivanis J, Dimopoulos T, Hadzigiannis J and Polyzonis M: The ultrastructure of the noninvolved urothelium of tumor bearing patients before and after interferon treatment. J Interferon Res 12: 397-402, 1992.
25. Stravoravdi P, Natsis K, Kirtsis P, Retalis G, Konstantinidis E and Polyzonis M: Ultrastructural study of the uninvolved urothelium of tumor-bearing patients after two years of intravesical interferon therapy. Eur Urol 29: 477-482, 1996.
26. Stravoravdi P, Natsis K, Kirtsis P, Toliou P, Konstantinidis E, Barich A and Polyzonis M: Ultrastructural study of the urothelial lysosomal system in patients with transitional cell carcinoma after transurethral resection and interferon therapy. J Exp Ther Oncol 1: 222-225, 1996.
27. Rhodes J, Jones DH and Bleehen NM: Increased expression of human monocyte HLA-DR antigens and Fc-gamma receptors in response to human interferon in vivo. Clin Exp Immunol 53: 739-743, 1983.
28. Jackson AM, Hawkyard SJ, Prescott S, Ritchie AWS, James K and Chisholm GD: An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines. J Urol 147: 207-211, 1992.
29. Tzai T-S and Lin S-N: Interferon-alpha can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes. J Urol 147: 523-527, 1992.
30. Natsis K, Toliou T, Stravoravdi P, Kirtsis P, Grekou A, Barich A, Konstantinidis E and Gigis P: Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study. Int J Clin Pharmacol Res 17: 31-36, 1997.
31. Alvarez-Mon M, Molto LM, Manzano L, Olivier C and Carballido JA: Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder. Anticancer Drugs 3(suppl1): 5-8, 1992.
32. Molto L, Alvarez-Mon M, Carballido J, Manzano L, Guillen C, Prieto A, Olivier C and Rodriguez-Zapata M: Intracavitary prophylactic treatment with interferon alpha2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer 70 1247-1251, 1994.
33. Molto L, Alvarez-Mon M, Carballido J, Olivier C, Gimeno F and Manzano L: Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer. Cancer 75: 2720-2726, 1995.
34. Mitropoulos D, Deliconstantinos G, Adamakis I, Zervas A, Karakaidos P and Gorgoulis VG: Changes in end products of nitric oxide in urine and induction of nitric oxide synthase expression in urinary bladder during intravesical instillations of interferon-α2b. J Interferon & Cytokine Res 24: 621-626, 2004.
35. Ratliff TL, Kavoussi LR and Catalona WJ: Role of fibronectin in intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 139: 410-414, 1988.
36. Kavoussi LR, Brown EJ, Ritchey JK and Ratliff TL: Fibronectin mediated bacillus Calmette-Guerin attachment to murine bladder mucosa: requirement for expression of an antitumor response. J Clin Invest 85 62-68, 1990.
37. Hudson MA, Brown EJ, Richey JK and Ratliff TL: Modulation of fibronectin-mediated Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51: 3726-3732, 1991.
38. Wiker HG and Harboe M: The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 56: 648-653, 1992.
39. Cheng DL, Shu W-P, Choi JCS, Margolis EJ, Droller MJ and Liu BC: Bacillus Calmette-Guerin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity. J Urol 152: 1275-1280, 1994.
40. Aslanzadeh J, Brown EJ, Quilalan SP, Ritchey JK and Ratliff TL: Characterization of soluble fibronectin binding to bacilli Calmette-Guerin. J Gen Microbiol 135: 2735-2741, 1989.
41. Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ and Ratliff TL: Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86: 83-88, 2000.
42. Schamhart DH, de Boer EC, Bevers RF, Kurth KH and Steerenberg PA: Mycobacterial adherence and BCG treatment of superficial bladder cancer. Prog Clin Biol Res 378: 75-80.
43. Becich MJ, Carroll S and Ratliff TL: Internalization of bacilli Calmette-Guerin by bladder tumor cells. J Urol 145: 1316-1324, 1991.
44. Kuroda K, Brown EJ, Telle WB, Russell DG and Ratliff TL: Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells: J Clin Invest 91: 69-76, 1993.
45. Ratliff TL, Gillen DP and Catalona WJ: Requirement of a thymus-dependent immune response for BCG-mediated antitumor activity. J Urol 137: 155-158, 1987.
46. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL and Catalona WJ: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150: 1018-1023, 1993.
47. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL and Bohle A: NK cells are essential for effective BCG immunotherapy. Int J Cancer 92: 697-702, 2001.
48. Lamm DL, Thor DE, Winters WD, Stogdill VD and Radwin HM: BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses. Cancer 48: 82-88, 1981.
49. Winters WD and Lamm DL: Antibody responses to bacillus Calmette-Guerin during immunotherapy in bladder cancer patients. Cancer Res 41: 2672-2676, 1981.
50. van der Sloot E, Kuster S, Bohle A, Braun J and Wood WG: Towards an understanding of the mode of action of bacillus Calmette-Guerin-therapy in bladder cancer treatment, especially with regard to the role of fibronectin. Eur J Clin Chem Clin Biochem 30: 503-511, 1992.
51. Bohle A, van der Sloot E, Richter E, Gerdes J, Wood WG and Jocham D: Binding to fibronectin (FN)-a prerequisite step? Investigations on the role of FN in intravesical BCG immunotherapy. Invest Urol (Berl) 5: 100-104, 1994.
52. Zlotta AR, Drowart A, van Vooren JP, Shekarsarai H, de Cock M, Pirson M, Palfliet K, Jurion F, Simon J, Schulman CC and Huygen K: Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy. J Urol 159: 1885-1891, 1998.
53. Zlotta AR, Drowart A, van Vooren JP, Simon J, Schulman CC and Huygen K: Evolution of cellular and humoral response against tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer. Acta Urol Belg 62: 63-68, 1994.
54. Zlotta AR, Drowart A, Huygen K, De Bruyn J, Shekarsarai H and Decock M: Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol 109: 157-165, 1997.
55. Zlotta AR, Drowart A, van Vooren J-P, de Cock M, Pirson M and Palfliet K: Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol 157: 492-498, 1997.
56. Sarica K, Baltaci S, Beduk Y, Suzer O, Kilic S, Ziya Muftuoglu Y and Gogus O: Evaluation of cellular immunity following bacillus Calmette-Guerin therapy in patients with superficial bladder cancer. Urol Int 54: 137-141, 1995.
57. Yoshimura K and Yamauchi T: Influence of intravesical bacillus Calmette-Guerin therapy on systemic immunological status. Int J Urol 4: 456-460, 1997.
58. Reyes E, Carballido J, Manzano L, Molto L, Olivier C and Alvarez-Mon M: The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients. Br J Cancer 79: 1162-1167, 1999.
59. van der Meijden AP, Steerenberg PA, van Hoogstraaten IM, Kerckhaert JA, Schreinemachers LM, Harthoorn-Lasthuizen EJ, Hagenaars AM, de Jong WH, Debruyne FM and Ruitenberg EJ: Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guerin. Cancer Immunol Immunother 28 287-295, 1989.
60. Hermann GG, Petersen KR, Zeuthen J and Steven K: Intravesical BCG therapy in bladder carcinoma. Effect of cytotoxicity, production and phenotype of peripheral blood mononuclear cells. Scand J Urol Nephrol 25: 269-273, 1991.
61. Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H and Saito Y: Systemic immune response after intravesical instillation of bacilli Calmette-Guerin (BCG) for superficial bladder cancer. Clin Exp Immunol 115: 131-135, 1999.
62. Elsasser-Beile U, Gutzeit O, Bauer S, Katzenwadel A, Schultze-Seemann W and Wettereauer U: Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas. J Urol 163: 296-299, 2000.
63. Kaempfer R, Gerez L, Farbstein H, Madar L, Hirschman O, Nussinovich R and Shapiro A: Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 14: 1778-1786, 1996.
64. Magno C, Melloni D, Gali A, Mucciardi G, Nicocia G, Morandi B, Melioli G and Ferlazzo G: The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2. Immunol Lett 81: 235-238, 2002.
65. Reale M, Intorno R, Tenaglia R, Feliciani C, Barbacane RC, Santoni A and Conti P: Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunol Immunother 51: 91-98, 2002.
66. Mitropoulos D, Deliconstantinos G, Zervas A, Giannopoulos A, Kyriakou G and Dimopoulos C: Oxidative stress of red blood cells during bacillus Calmette-Guerin intravesical instillations. In Vivo 14: 721-724, 2000.
67. Ratliff TL, Haaff EO and Catalona WJ: Interleukin-2 production during intravesical bacilli Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopathol 40: 375-379, 1986.
68. Haaff EO, Catalona WJ and Ratliff TL: Detection of interleukin-2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136: 970-974, 1986.
69. Fleischmann JD, Toossi Z, Ellner JJ, Wentworth DB, Ratliff TL and Imbembo AL: Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer 64: 1447-1454, 1989.
70. de Jong WH, de Boer EC, van der Meijden AP, Vegt P, Steerenberg PA, Debruyne FM and Ruitenberg EJ: Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guerin. Cancer Immunol Immunother 31 182-186, 1990.
71. Bohle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG and Flad HD: Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol 144: 59-64, 1990.
72. Bohle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J. Hofstetter AG and Flad HD: Detection of urinary TNF, IL 1 and IL 2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2: 175-181, 1990.
73. de Boer EC, de Jong WH, Steerenberg PA, van der Meijden AP, Aarden LA, Debruyne FM and Ruitenberg EJ: Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin. In Vivo 5: 671-677, 1991.
74. de Boer EC, de Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, de Groot ER, van der Meijden AP, Vegt PD, Debruyne FM and Ruitenberg EJ: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother 34: 306-312, 1992.
75. Balbay D, Bakkaloglu M, Ozen H, Tasar C, Ozkardes H, Remzi D and Barut A: Detection of urinary interleukin-2, interleukin-2 receptor, and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy. Urology 43: 187-190, 1994.
76. Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD and James K: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99: 369-375, 1995.
77. de Reijke TM, de Boer EC, Kurth KH and Schamhart DH: Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155: 477-482, 1996.
78. Jackson AM, Ivshina AV, Senko O, Kuznetsova A, Sundan A, O'Donnell MA, Clinton S, Alexandroff AB, Selby PJ, James K and Kuznetsov VA: Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis. J Urol 159: 1054-1063, 1998.
79. de Reijke TM, de Boer EC, Kurth KH and Schamhart DH: Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations? J Urol 161: 67-71, 1999.
80. Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, de la Taille A, Abbou CC and Chopin DK: T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 166: 2142-2147, 2001.
81. Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC and Chopin DK: Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 167: 364-367, 2002.
82. Watanabe E, Matsuyama H, Matsuda K, Ohmi C, Tei Y, Yoshihiro S, Ohmoto Y and Naito K: Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52 481-486, 2003.
83. Jackson AM, Alexandrov AB, Prescott S and James K: Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunol Immunother 40: 119-124, 1995.
84. Bettex-Galland M, Studer UE, Walz A, Dewald B and Baggiolini M: Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guerin administration. Eur Urol 19: 171-175, 1991.
85. de Boer EC, Somogyi L, de Reuiter GJ, de Reijke TM, Kurth KH and Schamhart DH: Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 25: 31-34, 1997.
86. Rabinowitz R, Smith DS, Tiemann DD and Hudson MA: Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients. J Urol 158 1728-1731, 1997.
87. Thalmann GN, Dewald B, Baggiolini M and Studer UE: Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 158: 1340-1344, 1997.
88. Thalmann GN, Sermier A, Rentsch C, Moehrle K, Cecchini MG and Studer UE: Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164: 2129-2133, 2000.
89. Sheryka E, Wheeler MA, Hausladen DA and Weiss RM: Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 62: 162-166, 2003.
90. H2 cytokine, following bacillus Calmette-Guerin immunotherapy of bladder cancer. Int J Oncol 9: 179-181, 1996.
91. Esuvaranathan K, Alexandroff AB, McIntyre M, Jackson AM, Prescott S, Chisholm GD and James K: Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol 154: 572-575, 1995.
92. Zhang Y, Khoo HE and Esuvaranathan K: Effects of bacillus Calmette-Guerin and interferon alpha-2B on cytokine production in human cancer cell lines. J Urol 161: 977-983, 1999.
93. Poppas DP, Pavlovich CP, Folkman J, Voest EE, Chen X, Luster AD and O'Donnell MA: Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52 268-276, 1998.
94. Prescott S, James K, Hargreave TB, Chisholm GD and Smyth JF: Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248-1251, 1990.
95. Jackson AM, Alexandrov AB, Gribben SC, Esuvaranathan K and James K: Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int J Cancer 55: 921-925, 1993.
96. Jackson AM, Alexandroff AB, McIntyre M, Esuvaranathan K, James K and Chisholm GD: Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol 47: 309-312, 1994.
97. Jackson AM, Lien E, Alexandroff AB, Prescott S, Espevik T, Jaames K, Selby PJ and Sundan A: Soluble urinary CD14 after intravesical bacilli Calmette-Guerin immunotherapy for carcinoma in situ. Br J Urol 80: 766-771, 1997.
98. de Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, Debruyne FM and Ruitenberg EJ: Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 19: 45-50, 1991.
99. de Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, Debruyne FM and Ruitenberg EJ: Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin. Cancer Immunol Immunother 33: 411-416, 1991.
100. McAveney KM, Gomella LG and Lattime EC: Induction of TH1- and TH2-associated cytokine MRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother 39: 401-406, 1994.
101. Shin JS, Park JH, Kim JD, Lee JM and Kim SJ: Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guerin. Clin Exp Immunol 100: 26-31, 1995.
102. Luo Y, Chen X and O'Donnell MA: Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and stimulation of BCG effect. Cytokine 21: 17-26, 2003.
103. Thanhauser A, Bohle A, Schneider B, Reiling N, Mattern T, Ernst M, Flad HD and Ulmer AJ: The induction of bacillus-Calmette-Guerin-activated killer requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40: 103-108, 1995.
104. O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE and Clinton SK: Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. J Immunol 163: 4246-4252, 1999.
105. Mendez-Samperio P, Ayala-Verdin HE and Trejo-Echeverria A: Interleukin-12 regulates the production of bacille Calmette-Guerin-induced interferon-gamma from human cells in a CD40-dependent manner. Scand J Immunol 50: 61-67, 1999.
106. Chen X, Luo Y, Yamada H and O'Donnell MA: BCG potentiates human chemokine induction in vivo and in vitro. J Urol 165(suppl): 114 (abstract 465), 2001.
107. Lage JM, Bauer WC, Kelley DR, Ratliff TL and Catalona WJ: Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer. J Urol 135: 916-919, 1986.
108. Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG and Flad H-D: Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53-58, 1990.
109. Prescott S, James K, Hargreave TB, Chisholm GD and Smyth JF: Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147 1636-1642, 1992.
110. Adolphs HD, Schwabe HW, Helpap B and Volz C: Cytomorphological and histological studies on the urothelium during and after chemoimmune prophylaxis. Urol Res 12: 129-133, 1984.
111. El-Demiry MI, Smith G, Ritchie AW, James K, Cumming JA, Hargreave TB and Chisholm GD: Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol 60: 543-548, 1987,
112. Prescott S, James K, Busuttil A, Hargreave T, Chisholm GC and Smyth J: HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 63: 264-269, 1989.
113. Prescott S, James K, Hargreave TB, Chisholm GD and Smyth JF: Immunopathological effects of intravesical BCG therapy. Prog Clin Biol Res 310: 93-105, 1989.
114. Stefanini GF, Bercovich E, Mazzeo V, Grigioni WF, Emili E, D'Errico A, Lo Cigno M, Tamagnini N and Mazzetti M: Class I and class II HLA antigen expression by transitional cell carcinoma of the bladder: correlation with T-cell infiltration and BCG treatment. J Urol 141: 1449-1453, 1989.
115. Flam TA, Chopin DK, Leleu C, Abbou CC, Steg A, Desligners S and Boccon-Gibod L: Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Calmette-Guerin endovesical immunotherapy for superficial bladder tumors. Eur Urol 17: 338-342, 1990.
116. Leong AS, Wannakrairot P, Lose J and Milios J: Bacillus Calmette-Guerin-treated superficial bladder cancer: correlation of morphology with immunophenotyping. J Pathol 162: 35-41, 1990.
117. Rubenstein M, Muchnik S, Chet M, Shaw MW, McKiel CF and Guinan PD: Tumor infiltrating lymphocytes: the effect of bacillus Calmette Guerin on helper/suppressor-T cell ratios of treated and untreated tumors. J Urol 146: 1650-1653, 1991.
118. Boccafoschi C, Montefiore F, Pavesi M, Pastomerlo M, Annoscia S, Lozzi C and Betta PG: Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma. Eur Urol 21: 304-308, 1992.
119. Bassi P, Milani C, Meneghini A, Garbeglio A, Aragona F, Zattoni F, Dalla Palma P, Rebuffi A and Pagano F: Clinical value of pathological changes after intravesical BCG therapy of superficial bladder cancer. Urology 40: 175-179, 1992.
120. Boccafoschi C, Montefiore F, Pavesi M, Pastomerlo M and Betta PG: Late effects of intravesical bacillus Calmette-Guerin immunotherapy on bladder mucosa infiltrating lymphocytes: an immunohistochemical study. Eur Urol 27: 334-338, 1995.
121. Patard JJ, Muscatelli-Groux B, Saint F, Popov Z, Maille P, Abbou C and Chopin D: Evaluation of local immune response after intravesical bacilli Calmette-Guerin treatment for superficial bladder cancer. J Urol 78: 709-714, 1996.
122. Honda S, Sakamoto Y, Fujime M and Kitagawa R: Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. Int J Urol 4: 68-73, 1997.
123. Reyes E, Carballido J, Prieto A, Molto L, Manzano L and Alvarez-Mon M: T Lymphocytes infiltrating the bladder wall of patients with carcinoma of urinary bladder are in vivo activated. Eur Urol 31: 472-477, 1997.
124. Saint F, Patard JJ, Groux Muscatelli B, Lefrere Belda MA, Gil Diez de Medina S, Abbou CC and Chopin DK: Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guerin treatment. BJU Int 88: 602-610, 2001.
125. Sander B, Damm O, Gustafsson B, Andersson U and Hakansson L: Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guerin. J Urol 156 536-541, 1996.
126. Betz SA, See WA and Cohen MB: Granulomatous inflammation in bladder wash specimens after intravesical bacillus Calmette-Guerin therapy for transitional cell carcinoma of the bladder. Am J Clin Pathol 99: 244-248, 1993.
127. Bruno S, Machi AM, Semino C, Meta M, Ponte M, Varaldo M, Curotto A, Ferlazzo G, Decensi A and Melioli G: Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer. Cancer Immunol Immunother 42: 47-54, 1996.
128. Gan YH, Mahendran R, James K, Lawrencia C and Esuvaranathan K: Evaluation of lymphocytic responses after treatment with bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer. Clin Immunol 90: 230-237, 1999.
129. Thurnher M, Ramoner R, Gastl G, Radmayr C, Bock G, Herold M, Klocker H and Bartsch G: Bacillus Calmette-Guerin mycobacteria stimulate human blood dendritic cells. Int J Cancer 70: 128-134, 1997.
130. Ramoner R, Rieser C, Herold M, Klocker H, Bartsch G, Stenzl A and Thurnher M: Activation of human dendritic cells by bacillus Calmette-Guerin. J Urol 159: 1488-1492, 1998.
131. Lattime EC, Gomella LG and McCue PA: Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res 52: 4286-4290, 1992.
132. Ikeda N, Toida I, Iwasaki A, Kawai K and Akaza H: Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guerin (BCG): a role of BCG internalization into tumor cells. Int J Urol 9: 29-35, 2002.
133. Jackson AM, Alexandrov AB, Prescott S, James K and Chisholm GD: Expression of adhesion molecules by bladder cancer cells: modulation by interferon-γ and tumor necrosis factor-α. J Urol 148: 1583-1586, 1992.
134. Hawkyard S, James K, Prescott S, Jackson AM, Ritchie AW, Smyth JF and Chisholm GD: The effects of recombinant interferon-γ on a panel of human bladder cancer cell lines. J Urol 145: 1078-1081, 1991.
135. Jackson AM, Prescott S, Hawkyard SJ, James K and Chisholm G: The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical Evans BCG therapy. Cancer Immunol Immunother 36: 25-30, 1993.
136. Catalona WJ, Oldham RK, Herberman RB, Djeu JY and Cannon GB: Lack of specificity of lymphocyte-mediated cytotoxicity against the bladder cancer cell line, T24. J Urol 118: 254-257, 1977.
137. Hermann GG, Petersen KR, Steven K and Zeuthen J: Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. J Clin Immunol 10: 311-320, 1990.
138. Jackson AM, Alexandrov AB, Prescott S, James K and Chisholm GD: Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leukocyte function-associated antigen-1. Immunology 76: 286-291, 1992.
139. Campbell SC, Tanabe K, Alexander JP, Edinger M, Tubbs RR and Klein EA: Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects. J Urol 151: 1385-1390, 1994.
140. Shemtov MM, Cheng DL, Kong L, Shu W-P, Sassaroli M, Droller MJ and Liu BC: LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy. J Urol 154: 269-274, 1995.
141. Pryor K, Goddard J, Goldstein D, Stricker P, Russell P, Golovsky D and Penny R: Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer 71 801-807, 1995.
142. Mizutani Y, Nio Y, Fukumoto M and Yoshida O: Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 69: 537-545, 1992.
143. Thanhauser A, Bohle A, Flad HD, Ernst M, Mattern T and Ulmer AJ: Induction of bacillus Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37: 105-111, 1993.
144. Bohle A, Thanhauser A, Ulmer AJ, Ernst M, Flad H-D and Jocham D: Dissecting the immunobiological effects of bacillus Calmette-Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150: 1932-1937, 1993.
145. Bohle A, Thanhauser A, Ulmer AJ, Mattern T, Ernst M, Flad HD and Jocham D: On the mode of action of intravesical bacillus Calmette-Guerin: in vitro characterization of BCG-activated killer cells. Urol Res 22: 185-190, 1994.
146. Brandau S, Bohle A, Thanhauser A, Ernst M, Mattern T, Ulmer AJ and Flad HD: In vitro generation of bacillus Calmette-Guerin-activated killer cells. Clin Infect Dis 31(Suppl.3) S94-S100, 2000.
147. Brandau S and Bohle A: Activation of natural killer cells by Bacillus Calmette-Guerin. Eur Urol 39: 518-524, 2001.
148. Haregewoin A, Soman G, Hom RC and Finberg RW: Human γδ T cells respond to mycobacterial heat-shock protein. Nature 340: 309-312, 1989.
149. + T lymphocytes by sonicated antigens of Mycobacterium tuberculosis: role in vitro in killing human bladder carcinoma cell lines. Scand J Immunol 38: 239-246, 1993.
150. Lee RK, Spielman J, Zhao DY, Olsen KJ and Podack ER: Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 157: 1919-1925, 1996.
151. Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD and Bohle A: Perforin-mediated lysis of tumor cells by Mycobacterium bovis bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 6: 3729-3738, 2000.
152. Suttmann H, Jocham D, Bohle A and Brandau S: The role of LFA-1 in the lysis of bladder cancer cells by bacillus Calmette-Guerin and interleukin 2-activated killer cells. Urol Res 30: 233-239, 2002.
153. Kurisu H, Matsuyama H, Ohmoto Y, Shimabukuro T and Naito K: Cytokine-mediated antitumor effect of bacillus Calmette-Guerin on tumor cells in vitro. Cancer Immunol Immunother 39: 249-253, 1994.
154. Pavlovich CP, Kraling BM, Stewart RJ, Chen X, Bochner BH, Luster AD, Poppas DP and O'Donnell MA: BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation. J Urol 163: 2014-2021, 2000.
155. Pareek G, Shevchuk M, Armenakas NA, Budak M and Fracchia JA: The effect of BCG on angiogenesis and cellular proliferation in recurrent superficial TCC of the bladder. Uro Oncology 4: 31-34, 2004.
156. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA and Griffiths TS: Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64: 3386-3390, 2004.
157. Rajala P, Kaasinen E, Rintala E, Jauhiainen K, Nurmi M, Alfthan O and Lahde M: Cytostatic effect of different strains of bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol Res 20: 215-217, 1992.
158. Jackson AM, Alexandroff AB, Fleming D, Prescott S, Chisholm GD and James K: Bacillus Calmette-Guerin (BCG) organisms directly alter the growth of bladder tumor cells. Int J Oncol 5: 697-703, 1994.
159. Pryor K, Stricker P, Russell P, Golovsky D and Penny R: Antiproliferative effects of bacillus Calmette-Guerin and Interferon alpha-2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 41: 309-316, 1995.
160. Zhang Y, Khoo HE and Esuvaranathan K: Effects of bacillus Calmette-Guerin and interferon-α-2B on human bladder cancer cells in vitro. Int J Cancer 71: 851-857, 1997.
161. Sasaki A, Kudoh S, Mori K, Takahashi N and Suzuki T: Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro? Urol Int 59: 142-148, 1997.
162. Saitoh H, Mori K, Kudoh S, Itoh H, Takahashi N and Suzuki T: BCG effects on telomerase activity in bladder cancer cell lines. Int J Clin Oncol 7: 165-170, 2002.
163. de Reijke TM, Vos PC, Bevers RF, de Muinck Keizer WH, Kurth KH and Schamhart DH: Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette Guerin (BCG). Urol Res 21: 349-352, 1993.
164. Bevers RF, de Boer EC, Kurth KH and Schamhart DH: BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Netw 9 181-186, 1998.
165. Chen F-H, Crist SA, Zhang G-J, Iwamoto Y and See WA: Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guerin through nuclear factor κB and AP-1 via an immediate early pathway. J Urol 168(suppl): 786, 2002.
166. Chen F, Zhang G, Iwamoto Y and See WA: Bacillus Calmette-Guerin initiates intracellular signalling in a transitional carcinoma cell line by cross-linking alpha 5 beta 1 integrin. J Urol 170: 605-610, 2003.
167. Mitropoulos D, Petsis D, Kyroudi-Voulgari A, Kouloukoussa M and Zervas A: The effect of intravesical bacillus Calmette-Guerin (BCG) instillations on the expression of inducible nitric oxide synthase (iNOS) in humans. Eur Urol 38: 516, 2000.
168. Swana HS, Smith SD, Perrota PL, Saito N, Wheeler MA and Weiss RM: Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol 161: 630-634, 1999.
169. Klotz T, Bloch W, Jacobs G, Niggemann S, Engelmann U and Addicks K: Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology 54: 416-419, 1999.
170. Wolf H, Haeckel C and Roessner A: Inducible nitric oxide synthase expression in human urinary bladder cancer. Virchows Arch 437 662-666, 2000.
171. Shochina M, Fellig Y, Sughayer M, Pizov G, Vitner K, Podeh D, Hochberg A and Ariel I: Nitric oxide synthase immunoreactivity in human bladder carcinoma. J Clin Pathol Mol Pathol 54: 248-252, 2001.
172. Ehsan A, Sommer F, Schmidt A, Klotz T, Koslowski J, Niggermann S, Jacobs G, Engelmann U, Addicks K and Bloch W: Nitric oxide pathways in human bladder carcinoma: The distribution of nitric oxide synthases, soluble guanyl cyclase, cyclic guanosine monophosphate, and nitrotyrosine. Cancer 95: 2293-2301, 2002.
173. Eijan AM, Piccardo I, Riveros MD, Sandes EO, Porcella H, Jasnis MA, De Lustig ES, Malagrino H, Pasik L and Casabe AR: Nitric oxide in patients with transitional bladder cancer. J Surg Oncol 81: 203-208, 2002.
174. Morcos E, Jansson OT, Adolfson J, Kratz G and Wiklund NP: Endogenously formed nitric oxide modulates cell growth in bladder cancer cell lines. Urology 53: 1252-1257, 1999.
175. Jansson OT, Morcos E, Brundin L, Lundberg JON, Adolfsson J, Soederhaell M and Wiklund NP: The role of nitric oxide in bacillus Calmette-Guerin mediated antitumor effects in human bladder cancer. Br J Cancer 78: 588-592, 1998.
176. Oh BR, Nakajima K, Ahn KY, Ryu SB, Park YI and Dahiya R: Nitric oxide synthase gene and protein expression are upregulated by bacille Calmette-Guerin in the rat bladder. Eur Urol 39: 349-356, 2001.
177. Morcos E, Jansson OT, Adolfsson J, Ehren I and Wiklund NP: Bacillus Calmette-Guerin induces long-term local formation of nitric oxide in the bladder via the induction of nitric oxide synthase activity in urothelial cells. J Urol 165: 678-682, 2001.
178. Samlowski WE, Yim CY and McGregor JR: Nitric oxide exposure inhibits induction of lymphokine-activated killer cells by inducing precursor apoptosis. Nitric Oxide 2: 45-56, 1998.
179. Wang Z-P, Chen Y-R, Zheng R-L, Lu J-Z and Wang J-J: Effects of reactive oxygen species on lymphokine-activated killer cells in patients with bladder cancer. Acta Pharmacol Sin 23: 257-262, 2002.